Use of Algorithms to Predict Disease: A Clinical Perspective
Authors: Levine Elliot 
Published: July 2024

Introduction: Artificial Intelligence (AI) has been the focus of many recent publications describing its use in a variety of medical specialties, yielding seemingly overwhelming positive success. Its dependence on a large volume of information from different sources requires a computerized analysis for its execution. Rather than explain the complexities of its operation, it is the intent of this communication to advance reasons for caution in its medical applications in Obstetrics and Gynecology (OBGYN) and elsewhere. Machine Learning (ML) represents a significant aspect of AI, and the concepts that help to explain its function are unique and different from how data is traditionally visualized and statistically described. AI and the algorithmic approach to making diagnoses has become popularized recently, along with the use of prediction models for the screening of targeted populations of patients for possible disease. In OBGYN, there may be value in predicting clinical circumstances that may not otherwise be predicted, but applying these formulas should be measured against the interventions which can have the desired clinical outcomes. For example, does it matter if we can predict the occurrence of postpartum hemorrhage (PPH) if we know there is a finite risk of it happening, and that we need to always be prepared for it, regardless of whatever predicted risk there may be? Moreover, there appears little that can prevent PPH at the site of care when a prediction is made. Another predictable clinical scenario, shoulder dystocia (SD), can also be considered in this light. We may need to contrast these prediction models with scenarios for which there may be an intervention that can be offered to prevent it from occurring. Preeclampsia (PE) is such an example of a condition that can be predicted by AI (better than by statistical measures), for which there may be interventions that may diminish its likelihood of occurrence and severity in later pregnancy (e.g. with low-dose aspirin, LDA). A project was conducted to contrast the use of clinical AI applications in these described circumstances (PPH, SD, and PE). Methods: The medical literature was searched in PubMed for articles having the keywords of “obstetrics gynecology” and “algorithms” and “clinical success”, published in the past 5 years. 17 articles which are clinically relevant to the specialty were found, and three specifically impactful articles were selected to compare their clinical utility, relative to what was mentioned in the Introduction. The three citations include: 1) Tsur A, et al: Development and validation of a machine-learning model for prediction of shoulder dystocia. Ultrasound Obstet Gynecol. 2020 Oct;56(4):588-596. 2) Venkatesh VV, et al: Machine Learning and Statistical Models to Predict Postpartum Hemorrhage. Obstet Gynecol 2020;135(4):935-944. 3) Jhee JH, et al: Prediction model development of late-onset preeclampsia using machine learning-based methods. PLoS ONE 2019; 14(8):e02212202. Results: 1. 0.44% of over 53,000 births had SD, predicted 87% of the time with ML. The clinical benefit of its prediction has not been demonstrated, regarding the value of preparedness for when it occurs (approximately one in 200 vaginal births). For example, the time it takes to execute the necessary maneuvers for delivery when SD is recognized may not at all relate to its prediction. 2. 4.8% of over 152,000 births had PPH, predicted 93% of the time with ML. Whether PPH is recognized at vaginal or cesarean birth, the cascade of actions which are necessary for its successful management, may not be employed any more quickly whether it is predicted or not. Preparedness for its occurrence is a necessary skill for every obstetric professional at every delivery. 3. 4.7 % of about 11,000 patients had late term (≥ 34 weeks of gestation) PE, predicted 92% of the time with gradient boosting ML. PE has a finite occurrence in late pregnancy, causing premature birth and other related perinatal morbidities, for which LDA has been shown to improve pregnancy outcome if initiated prior to 16 weeks of gestation. The initiation of such prophylaxis has been shown to not regularly occur for those at increased risk. It appears that ML may be able to cause initiation of prophylaxis which may not otherwise sufficiently occur. Therefore, the clinical benefit of prediction may have important potential value in this case, if prompting the initiation of prophylaxis, resulting in decreased incidence of PE complications. 3. 3. 4.7 % of about 11,000 patients had late term (≥ 34 weeks of gestation) PE, predicted 92% of the time with gradient boosting ML. Discussion: While the ability to predict clinical events may seem to be attractive, the clinical outcomes in those circumstances must be measured. Three such examples of prediction models were compared (SD, PPH, and PE), and the potential difference in clinical outcome is described. The clinical value of AI should indeed be recognized. However, caution is advised before resources are provided for it without the necessary demonstration of clinical benefit from such AI prediction models.